The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon. Horizon CombinatoRx will provide access to the unique cHTS platform and Chalice analytics software, which enables the screening and analysis of thousands of complementary drug combinations. By combining the cHTS platform with Horizon's GENESIS (rAAV, CRISPR & ZFN) gene editing platform and X-MAN isogenic cell line technology, Horizon CombinatoRx will be able to offer services, including novel phenotypic cell-based screens with compound siRNA, shRNA, and sgRNA (for CRISPR based screening) libraries. These new services will offer a powerful solution for drug discovery and development organizations to explore the efficacy and mechanistic synergies of thousands of drug combinations, with the potential to identify personalized medicine regimens for the treatment of serious diseases.